We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Advances a Consumer-Centric Digital Health Platform
Read MoreHide Full Article
Key Takeaways
Hims & Hers unifies telehealth visits, pharmacy fulfillment and ongoing care in one platform.
HIMS adds hormone therapy, Labs, advanced diagnostics and multi-cancer detection to deepen personalization.
GDRX adds ED subscriptions and Rx savings tools; MED expands OPTAVIA access, new 2026 systems.
Hims & Hers Health, Inc. (HIMS - Free Report) has built its business around a deeply consumer-centric approach, reimagining how individuals access and engage with healthcare. At its core is a digital-first platform designed to shift traditional care into a more personalized, accessible and convenient experience. By integrating telehealth consultations, digital prescriptions, pharmacy fulfillment and ongoing clinical management, HIMS enables users to seamlessly navigate their healthcare journey — from discovery to treatment and follow-up — through a single interface. This model not only reduces barriers such as stigma, cost and limited provider access, but also allows customers to receive tailored treatment plans supported by continuous engagement and subscription-based care.
Hims & Hers’ recent initiatives further reinforce this customer-first philosophy by expanding both access and personalization. New offerings such as hormone therapies, comprehensive laboratory testing and multi-cancer early detection aim to give users deeper insights into their health while enabling more proactive and preventive care. The launch of Labs and advanced diagnostics reflects a broader push toward data-driven, individualized healthcare, empowering customers to better understand and act on their health metrics. At the same time, innovations like personalized weight loss programs and condition-specific specialties — spanning areas such as menopause and testosterone care — highlight HIMS’ focus on addressing underserved needs with tailored solutions.
This consumer-centric model is also scaling globally, supported by strategic expansions and acquisitions aimed at extending access to personalized care across geographies. By combining technology, clinical expertise and localized delivery, Hims & Hers continues to position itself as a platform where healthcare is not only more accessible but also increasingly aligned with individual needs and preferences.
GDRX & MED Driving Consumer-Centric Health Models
GoodRx Holdings, Inc.’s (GDRX - Free Report) consumer-centric model focuses on making prescription access simpler, more affordable and easier to navigate. GoodRx combines transparent pricing with digital tools that help consumers compare options, secure savings and access care more directly. GoodRx’s newer offerings extend that approach, including its erectile dysfunction subscription service that integrates consultation, prescription and delivery, along with RxSmartSaver and employer-backed programs that reduce out-of-pocket costs and expand access to high-impact medications.
Medifast, Inc.’s (MED - Free Report) consumer-centric model is built around a coach-guided, science-backed system that delivers personalized metabolic health solutions through human connection, accountability and community support. Medifast integrates clinically developed products with tailored plans and behavioral coaching, enabling better outcomes and sustained engagement. Medifast has enhanced accessibility through HSA and FSA eligibility for OPTAVIA and continues to innovate with new metabolic health products and systems launching in 2026, reinforcing its focus on holistic, client-centric care.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 38.2% year to date, underperforming the industry’s decline of 25.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.5X is lower than the industry’s average of 3.2X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 9.4% decline compared with 2025.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Advances a Consumer-Centric Digital Health Platform
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) has built its business around a deeply consumer-centric approach, reimagining how individuals access and engage with healthcare. At its core is a digital-first platform designed to shift traditional care into a more personalized, accessible and convenient experience. By integrating telehealth consultations, digital prescriptions, pharmacy fulfillment and ongoing clinical management, HIMS enables users to seamlessly navigate their healthcare journey — from discovery to treatment and follow-up — through a single interface. This model not only reduces barriers such as stigma, cost and limited provider access, but also allows customers to receive tailored treatment plans supported by continuous engagement and subscription-based care.
Hims & Hers’ recent initiatives further reinforce this customer-first philosophy by expanding both access and personalization. New offerings such as hormone therapies, comprehensive laboratory testing and multi-cancer early detection aim to give users deeper insights into their health while enabling more proactive and preventive care. The launch of Labs and advanced diagnostics reflects a broader push toward data-driven, individualized healthcare, empowering customers to better understand and act on their health metrics. At the same time, innovations like personalized weight loss programs and condition-specific specialties — spanning areas such as menopause and testosterone care — highlight HIMS’ focus on addressing underserved needs with tailored solutions.
This consumer-centric model is also scaling globally, supported by strategic expansions and acquisitions aimed at extending access to personalized care across geographies. By combining technology, clinical expertise and localized delivery, Hims & Hers continues to position itself as a platform where healthcare is not only more accessible but also increasingly aligned with individual needs and preferences.
GDRX & MED Driving Consumer-Centric Health Models
GoodRx Holdings, Inc.’s (GDRX - Free Report) consumer-centric model focuses on making prescription access simpler, more affordable and easier to navigate. GoodRx combines transparent pricing with digital tools that help consumers compare options, secure savings and access care more directly. GoodRx’s newer offerings extend that approach, including its erectile dysfunction subscription service that integrates consultation, prescription and delivery, along with RxSmartSaver and employer-backed programs that reduce out-of-pocket costs and expand access to high-impact medications.
Medifast, Inc.’s (MED - Free Report) consumer-centric model is built around a coach-guided, science-backed system that delivers personalized metabolic health solutions through human connection, accountability and community support. Medifast integrates clinically developed products with tailored plans and behavioral coaching, enabling better outcomes and sustained engagement. Medifast has enhanced accessibility through HSA and FSA eligibility for OPTAVIA and continues to innovate with new metabolic health products and systems launching in 2026, reinforcing its focus on holistic, client-centric care.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 38.2% year to date, underperforming the industry’s decline of 25.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.5X is lower than the industry’s average of 3.2X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 9.4% decline compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.